Piper Sandler downgrades Biogen as Alzheimer's drug hits another speedbump

thumbnail
Hannah Miao@hannahmiao_
WATCH LIVE
A sign marks a Biogen facility in Cambridge, Massachusetts.
Brian Snyder | Reuters

Piper Sandler on Wednesday downgraded Biogen after the biotechnology company faced another hiccup in the rollout of its Alzheimer's drug.